These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18396750)

  • 1. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
    de Suray N; Pranger D; Brenard R
    Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation.
    Galati G; Gentilucci UV; Sansoni I; Spataro S; Di Matteo FM; Zardi EM; Grasso RF; Avvisati G; Afeltra A; Picardi A
    Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):233-6. PubMed ID: 19212214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
    Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
    Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
    Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
    Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 V617F Mutation Testing in Patients Presenting With Hepatic and Portal Vein Thrombosis.
    Foucar CE; Stein BL
    JAMA; 2017 Jun; 317(21):2228-2229. PubMed ID: 28586872
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
    Gianotti R; Charles H; Hymes K; Chandarana H; Sigal S
    World J Gastroenterol; 2014 Oct; 20(39):14495-9. PubMed ID: 25339837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event].
    Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G
    J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
    Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
    Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant diagnosis of myeloproliferative neoplasm and non-Hodgkin's lymphoma in a patient with portal vein thrombosis.
    Papageorgiou MV; Alexopoulou A; Kontopidou F; Filiotou A; Koskinas J; Pectasides D
    Anticancer Res; 2011 Apr; 31(4):1467-9. PubMed ID: 21508404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
    Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
    Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
    De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
    Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
    [No Abstract]   [Full Text] [Related]  

  • 12. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
    Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
    Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
    Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
    Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
    Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
    [No Abstract]   [Full Text] [Related]  

  • 15. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
    Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
    Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
    [No Abstract]   [Full Text] [Related]  

  • 16. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
    Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
    Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
    Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
    Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
    Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
    Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.
    P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W
    Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
    Hexner EO
    Curr Opin Hematol; 2007 Sep; 14(5):450-4. PubMed ID: 17934351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.